Therapeutics
LU25-109
Quick Links
Overview
Name: LU25-109
Therapy Type: Small Molecule (timeline)
Target Type: Cholinergic System (timeline)
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Discontinued)
Approved for: None
Background
LU25-109 is a selective partial M1 agonist and an M2/M3 antagonist.
Last Updated: 12 Dec 2013
References
No Available References
Further Reading
No Available Further Reading
Comments
No Available Comments
Make a Comment
To make a comment you must login or register.